TABLE 3.
Selected confirmed peptide responses identified in the first 12 weeks postinfection in early controllers and rapid progressors
| Progressor | Total SFU/106 PBMCa | Breadthb | HLA background | Selected confirmed peptides | Previously published HLA restricted epitopesc | ||
|---|---|---|---|---|---|---|---|
| Early controllers | |||||||
| CAP045 | 11,400 | 8 | A*2301/2902 | B*1510/4501 | Cw*0602/1601 | Vif p10, Rev p7-8, Nef p33-34 | Vif, WHLGHGVSI (B*1510); Rev, IHSISERIL (B*1510); Nef, RYPLTFGW (A*2301) |
| CAP061 | 345 | 3 | A*6602/6802 | B*1401/4201 | Cw*0802/1701 | ND | |
| CAP222 | 2,970 | 5 | A*3001/3303 | B*5301/8101 | Cw*0401/- | Gag p25, Nef p17-18 | Gag, TPQDLNTML (A*4201, B*8101, B*0702); Nef, RPQVPLRPM (B*4201), QVPLRPMTYK (A*0301) |
| CAP269 | 0 | 0 | A*0205/6802 | B*0702/5802 | Cw*0602/0611 | Nil | |
| Rapid progressors | |||||||
| CAP008 | 9,165 | 9 | A*2301/- | B*0801/1510 | Cw*0701/1601 | Gag p4, Pol p64, Rev p7-8, Env p106-7, Nef p26-27 | Gag, HYMLKHLVW (A*2301, A*2402); Pol, IYQEPFKNL (A*2301, A*2402); Rev, IHSISERIL (B*1510); Env, LQREWEVLKYLGSLVQYW; Nef, KRQDILDLWIY (Cw*0701) |
| CAP037 | 5,130 | 4 | NDd | ND | ND | Pol p51, Nef p2-3, Nef p33-34 | Pol, TVQPIQLPEKDSWTVNDI; Nef, AVRERMRRT (B7, B8), RYPLTFGW (A*2301), YPLTFGWCF (B*5301, B*18, B*35) |
| CAP065 | 5,950 | 11 | A*2301/6802 | B*1510/5802 | Cw*0511/0611 | Pol p77-78, Vpr p4, Vif p2, Env p77 | Pol, GAETFYVDGA (A*6802); Env, RYLKDQQLL (A*2301, A*2402) |
| CAP069 | 560 | 3 | A*0301/2301 | B*1503/5802 | Cw*0210/0602 | Vif p4, Vif p8-9, Nef p19-21 | Vif, HIPLGEARLVIKTYWGL; Nef, QVPLRPMTYK (A*0301), KAAFDLSFF (B*57) |
| CAP206 | 8,040 | 10 | A*3204/7412 | B*0702/4403 | Cw*0210/0702 | Env p54, Nef p32-33 | Env, RIKQIINMW (A*3201); Nef, TPGPGVRYPL (B*0702) |
| CAP210 | 2,850 | 6 | A*6802/- | B*1510/- | Cw*0304/- | Gag p40-42, Vif p6, Vpr p6 | Gag, YVDRFFKTL (Cw*0303); Vpr, ETYGDTWTGV (A*6802) |
| CAP224 | 1,985 | 6 | ND | ND | ND | Vif p6, Vif p21, Vpr p4, Nef p17-19 | Vif, HPKVSSEVHI (B*4201); Vpr, FPRPWLHGL (B*0702, B*4201, B*8101); Nef, RPQVPLRPM (B*4201), QVPLRPMTYK (A*0301) |
| CAP258 | 12,440 | 9 | A*2301/2902 | B*4101/4201 | Cw*1701/- | Pol p54-55, Vif p6-7, Vpr p4, Vpu p7, Env p27, Nef p33-34 | Pol, YPGIKVRQL (B*4201); Vif, HPKVSSEVHI (B*4201); Vpr, FPRPWLHGL (B*4201); Vpu, ERAEDSGNESEGDTEELSA; Env, SFDPIPIHY (A*29); Nef, RYPLTFGW (A*2301) |
a
Total ELISPOT assay response. Means: early controllers, 3,679 ± 5,315; rapid progressors, 5,765 ± 3,992.
b
Breadth at 3 months postinfection. Means: early controllers, 4 ± 3.4; rapid progressors, 7 ± 3.
c
Previously identified HLA restricted epitopes corresponding to participant HLA type (23).
d
ND, not determined.